MARKET

JUNS

JUNS

JUPITER NEUROSCIENCES, INC.
NASDAQ
1.860
-0.280
-13.08%
After Hours: 1.770 -0.09 -4.84% 17:57 11/12 EST
OPEN
2.130
PREV CLOSE
2.140
HIGH
2.340
LOW
1.785
VOLUME
44.68K
TURNOVER
--
52 WEEK HIGH
103.50
52 WEEK LOW
1.785
MARKET CAP
2.45M
P/E (TTM)
-0.1002
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at JUNS last week (1102-1106)?
Weekly Report · 3d ago
Weekly Report: what happened at JUNS last week (1026-1030)?
Weekly Report · 11/02 09:14
Weekly Report: what happened at JUNS last week (1019-1023)?
Weekly Report · 10/26 09:14
Weekly Report: what happened at JUNS last week (1012-1016)?
Weekly Report · 10/19 09:14
Weekly Report: what happened at JUNS last week (1005-1009)?
Weekly Report · 10/12 09:15
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 10/07 12:05
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 10/06 21:05
Jupiter Neurosciences Starts Phase 2a Parkinson's Trial Of JOTROL
NASDAQ · 10/06 15:42
More
About JUNS
Jupiter Neurosciences, Inc. is a clinical-stage biopharmaceutical company advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer market with its Nugevia product line. The Company's pharmaceutical product pipeline is built around its proprietary platform product, JOTROL, an enhanced oral formulation of resveratrol. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Its segments include premium nutritional supplements, and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. The Company's Nugevia product line supplements space, supporting mental clarity, skin health, and mitochondrial function. It is also focused on a Phase IIa clinical study in Parkinson's disease. It also has rights in ALA-002.

Webull offers Jupiter Neurosciences Inc stock information, including NASDAQ: JUNS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JUNS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JUNS stock methods without spending real money on the virtual paper trading platform.